Systemic Opioid Elimination After Implantation of an Intrathecal Drug Delivery System Significantly Reduced Health‐Care Expenditures. Issue 3 (17th February 2015)
- Record Type:
- Journal Article
- Title:
- Systemic Opioid Elimination After Implantation of an Intrathecal Drug Delivery System Significantly Reduced Health‐Care Expenditures. Issue 3 (17th February 2015)
- Main Title:
- Systemic Opioid Elimination After Implantation of an Intrathecal Drug Delivery System Significantly Reduced Health‐Care Expenditures
- Authors:
- Hatheway, John A.
Caraway, David
David, Guy
Gunnarsson, Candace
Hinnenthal, Jennifer
Ernst, Amanda R.
Saulino, Michael - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ner12278-sec-0001" sec-type="section"> <title>Objective</title> <p>To compare health‐care expenditures over a 12‐month horizon for chronic pain patients with implanted intrathecal drug delivery systems (IDDS) who eliminated or continued systemic opioids postimplant.</p> </sec> <sec id="ner12278-sec-0002" sec-type="section"> <title>Methods</title> <p>Claims data from commercial and Medicare databases were searched for patients who had an IDDS, used systemic opioids before implant, and had 12 months pre‐ and 13 months postimplant continuous medical and pharmacy coverage. The number and characteristics of patients who eliminated or continued systemic opioids were determined at four times postimplant: 30 days (allowing a systemic opioid washout period), 120 days, 150 days, and 210 days. Multivariable models evaluated the effect of eliminating opioids on health‐care expenditures at each of those times.</p> </sec> <sec id="ner12278-sec-0003" sec-type="section"> <title>Results</title> <p>Three hundred eighty‐nine patients met inclusion criteria, and 51% completely eliminated systemic opioids (12% within the 30‐day washout and an additional 39% by the end of the one‐year horizon). Systemic opioid elimination within 120 to 210 days postimplant was associated with a reduction of $3, 388 to $4, 465 in inpatient and outpatient expenditures, and $4, 689 to $5, 571 in inpatient, outpatient, and<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ner12278-sec-0001" sec-type="section"> <title>Objective</title> <p>To compare health‐care expenditures over a 12‐month horizon for chronic pain patients with implanted intrathecal drug delivery systems (IDDS) who eliminated or continued systemic opioids postimplant.</p> </sec> <sec id="ner12278-sec-0002" sec-type="section"> <title>Methods</title> <p>Claims data from commercial and Medicare databases were searched for patients who had an IDDS, used systemic opioids before implant, and had 12 months pre‐ and 13 months postimplant continuous medical and pharmacy coverage. The number and characteristics of patients who eliminated or continued systemic opioids were determined at four times postimplant: 30 days (allowing a systemic opioid washout period), 120 days, 150 days, and 210 days. Multivariable models evaluated the effect of eliminating opioids on health‐care expenditures at each of those times.</p> </sec> <sec id="ner12278-sec-0003" sec-type="section"> <title>Results</title> <p>Three hundred eighty‐nine patients met inclusion criteria, and 51% completely eliminated systemic opioids (12% within the 30‐day washout and an additional 39% by the end of the one‐year horizon). Systemic opioid elimination within 120 to 210 days postimplant was associated with a reduction of $3, 388 to $4, 465 in inpatient and outpatient expenditures, and $4, 689 to $5, 571 in inpatient, outpatient, and drug expenditures.</p> </sec> <sec id="ner12278-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Fifty‐one percent of patients completely eliminated systemic opioids in the year after IDDS implant. This elimination resulted in a 10% to 17% reduction in yearly inpatient, outpatient, and drug expenditures.</p> </sec> </abstract> … (more)
- Is Part Of:
- Neuromodulaton. Volume 18:Issue 3(2015:May/Jun.)
- Journal:
- Neuromodulaton
- Issue:
- Volume 18:Issue 3(2015:May/Jun.)
- Issue Display:
- Volume 18, Issue 3 (2015)
- Year:
- 2015
- Volume:
- 18
- Issue:
- 3
- Issue Sort Value:
- 2015-0018-0003-0000
- Page Start:
- 207
- Page End:
- 213
- Publication Date:
- 2015-02-17
- Subjects:
- Central nervous system -- Physiology -- Periodicals
Central nervous system -- Diseases -- Periodicals
616.8 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1525-1403 ↗
https://www.sciencedirect.com/journal/neuromodulation-technology-at-the-neural-interface ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/ner.12278 ↗
- Languages:
- English
- ISSNs:
- 1094-7159
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.504100
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3294.xml